SEC Company Response from Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425) (MIRM) — Jun 6, 2022
Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425)
Date: June 6, 2022 · CIK: 0001759425 · Accession: 0001193125-22-167948
AI Filing Summary & Sentiment
File numbers found in text: 333-265210
Letter
Mirum Pharmaceuticals, Inc.
950 Tower Lane, Suite 1050
Foster City, CA 94404
June 6, 2022
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C.
Attn: Margaret Schwartz
RE: Mirum Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 25, 2022
File No. 333-265210
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on June 9, 2022, or as soon thereafter as is practicable.
Thank you for your assistance. If you should have any questions, please contact Alexa Ekman of Cooley LLP, counsel to the Registrant, at (858) 550-6183.
MIRUM PHARMACEUTICALS, INC.
By:
/s/ Christopher Peetz
Christopher Peetz
President and Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP Mirum Pharmaceuticals, Inc. 950 Tower Lane, Suite 1050 Foster City, CA 94404 June 6, 2022 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Margaret Schwartz RE: Mirum Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 25, 2022 File No. 333-265210 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on June 9, 2022, or as soon thereafter as is practicable. Thank you for your assistance. If you should have any questions, please contact Alexa Ekman of Cooley LLP, counsel to the Registrant, at (858) 550-6183. MIRUM PHARMACEUTICALS, INC. By: /s/ Christopher Peetz Christopher Peetz President and Chief Financial Officer